Evidence map›Paper›PMID 42382758›Full record

ReviewFrontiers in immunology2026

Waldenström macroglobulinemia-associated renal AL amyloidosis: a case report and literature review.

Jianping Zhang, Zhifeng Li, Huiping Chen, Xiaoyan Bian, Di Zhao, Zhu Lin, Tiekun Li, Yanlin Zhang

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianping ZhangDepartment of Nephrology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.
Zhifeng LiDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Huiping ChenExpert Consultation Office, Jinling Hospital, Nanjing, China.
Xiaoyan BianDepartment of Nephrology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.
Di ZhaoDepartment of Nephrology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.
Zhu LinDepartment of Nephrology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.
Tiekun LiNanjing Kingmed Diagnostics, Nanjing, China.
Yanlin ZhangDepartment of Nephrology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoma, characterized by lymphoplasmacytic infiltration of bone marrow and the existence of monoclonal IgM in circulation. Renal AL amyloidosis is an uncommon complication of WM, and its treatment is an enormous challenge to clinicians. This report describes a 71-year-old woman who presented with a 10-month history of recurrent bilateral lower extremity edema and a progressive fatigue. Physical and laboratory examinations revealed serum monoclonal IgMλ, nephrotic syndrome, moderate anemia and mild enlargement of bilateral inguinal superficial lymph nodes. Bone marrow aspiration demonstrated clonal lymphoplasmacytic infiltration, lymph node biopsy was consistent with lymphoplasmacytic lymphoma, and peripheral blood testing confirmed the presence of the

Indexed as

Immunoglobulin Light-chain AmyloidosisKidney DiseasesWaldenstrom MacroglobulinemiaAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideFemaleHumansMyeloid Differentiation Factor 88RituximabBendamustine HydrochlorideMYD88 protein, humanMyeloid Differentiation Factor 88RituximabAL amyloidosischemoimmunotherapykidneyMYD88 L265P mutationpulmonary infectiontoxicityWaldenström macroglobulinemia

Identifiers

PMID42382758
PMCPMC13314422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.